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Background: Electronic healthcare records (EHR) are increasingly used in epidemiological 
studies but are often viewed as lacking quality compared to randomised control trials and 
prospective cohorts. Studies of patients with chronic obstructive pulmonary disease (COPD) 
often use the rate of forced expiratory volume in 1 second (FEV1) decline as an outcome; 
however, its definition and robustness in EHR have not been investigated. We aimed to 
investigate how the rate of FEV1 decline differs by the criteria used in an EHR database.
Methods: Clinical Practice Research Datalink and Hospital Episode Statistics were used. 
Patient populations were defined using 8 sets of criteria around repeated FEV1 measure-
ments. At a minimum, patients had a diagnosis of COPD, were ≥35 years old, were current 
or ex-smokers, and had data recorded from 2004. FEV1 measurements recorded during 
follow-up were identified. Thereafter, eight populations were defined based on criteria 
around: i) the exclusion of patients or individual measurements with potential measurement 
error; ii) minimum number of FEV1 measurements; iii) minimum time interval between 
measurements; iv) specific timing of measurements; v) minimum follow-up time; and vi) the 
use of linked data. For each population, the rate of FEV1 decline was estimated using mixed 
linear regression.
Results: For 7/8 patient populations, rates of FEV1 decline (age and sex adjusted) were 
similar and ranged from −18.7mL/year (95% CI −19.2 to −18.2) to −16.5mL/year (95% CI 
−17.3 to −15.7). Rates of FEV1 decline in populations that excluded patients with potential 
measurement error ranged from −79.4mL/year (95% CI −80.7 to −78.2) to −46.8mL/year 
(95% CI −47.6 to −46.0).
Conclusion: FEV1 decline remained similar in a COPD population regardless of number of 
FEV1 measurements, time intervals between measurements, follow-up period, exclusion of 
specific FEV1 measurements, and linkage to HES. However, exclusion of individuals with 
questionable data led to selection bias and faster rates of decline.
Keywords: electronic healthcare records, spirometry, COPD, lung function
Introduction
Electronic health care record (EHR) databases consist of data routinely collected as 
part of clinical care and are often used for healthcare research. Whilst EHR 
databases have many strengths, one concern is that data are not collected for the 
purpose of research and that when tests are undertaken, they are not done so at 
routine intervals as they would be in arandomised control trial (RCT), nor is the 
reason for a test being undertaken at that specific point in time always known.1 
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EHR databases differ from RCTs or prospective cohort 
studies, which have structured data collection where data 
are collected at specific times for research purposes, by 
specific healthcare technicians, with specific equipment 
following specific protocols. EHRs are becoming increas-
ingly used in epidemiological research; however, they are 
often viewed as lacking quality.
In studies of people with chronic obstructive pulmon-
ary disease (COPD), longitudinal spirometry measure-
ments, such as forced expiratory volume in 1 second 
(FEV1), are often used to estimate lung function decline, 
a common marker of disease progression.2 Lung function 
decline is important as it is associated with quality of life, 
symptom burden, and mortality.3,4 Unlike RCTs and 
cohort studies, the sporadic nature of lung function mea-
surements recorded in EHR can lead to greater apparent 
variation in lung function in COPD patients. This could be 
due to measurement error, the number of measurements 
over follow-up, time intervals between measurements, fol-
low-up time, and the reason or time at which lung function 
measures are recorded by healthcare practitioners.
The Clinical Practice Research Datalink (CPRD) is 
a routinely collected EHR database of general practices in 
the UK and contains clinical patient information that is 
recorded at general practices during consultations. In this 
setting, spirometry measurements in COPD patients are 
performed by healthcare practitioners during visits to the 
general practice. The quality and outcomes framework 
(QOF) for COPD incentivises healthcare practitioners in 
general practice to perform spirometry every 15 months in 
COPD patients.5 A previous validation study of spirometry 
recordings in CPRD found that more than 96% of record-
ings had adequate quality whereby a valid interpretation 
could be made by a respiratory physician.6 Despite this, it 
is possible that other factors, such as timings of measure-
ments, time intervals, and follow-up time, could lead to 
differences in longitudinal changes in lung function decline.
We aimed to investigate the rate of FEV1 decline and 
how variation in FEV1 differs by the criteria used to define 
the rate of FEV1 decline in CPRD, a routinely collected 
database. Specifically, we aimed to investigate how criteria 
around measurement error, the number of FEV1 measure-
ments, timing of measurements, follow-up time, and use of 
additional linked databases may lead to differences in 
FEV1 decline estimates using CPRD. With the ever- 
growing use of EHR data for cohort studies and pragmatic 
trials, it is important to understand how robust EHR 
derived lung function decline is as an outcome.
Methods
Patient Eligibility Criteria
CPRD-GOLD (GOLD database of CPRD) was used and 
linked to a secondary care database, Hospital Episode 
Statistics (HES). CPRD contains clinical information on 
patients recorded at the general practices, such as diagnoses, 
prescriptions, consultation information, referrals, and tests 
performed (e.g., spirometry). HES contains information on 
secondary care processes for patients registered at general 
practices in England who are eligible for linkage with 
CPRD. In this study, COPD patients were identified using 
a validation definition of COPD in CPRD.7 COPD patients 
were identified if they had a clinical diagnosis of COPD, 
were over 35 years of age, and were smokers or ex-smokers. 
The start of follow-up (index date) was the first FEV1 
measurement date after the following criteria were met: i) 
COPD diagnosis; ii) date of registration with current gen-
eral practice; iii) date at which data recorded at a general 
practice were deemed to be of research quality (“up-to- 
standard”); iv) date at age 35; and v) after the implementa-
tion of QOF from the 1st January 2004. End of follow-up 
was the first date of the following: i) death date; ii) date at 
which the patient transferred to a non-CPRD GP; or iii) the 
31st December 2017. Figure 1 describes the study design 
used to create this base population.
FEV1 Measurements
FEV1 measurements recorded between the index date and 
the end of follow-up were identified. FEV1 measurements 
were recorded in millilitres. Measurements recorded in 
litres were transformed to mL and measurements that 
were higher than 7 litres were excluded (94.8% of all 
measurements over follow-up were below 7 litres). A cut 
off 7 L was used based on the average total lung capacity 
for a healthy adult male. Whilst an FEV1 measurement of 
7 L would be considered high in COPD patients, a dis-
tribution of FEV1 measurements was considered based off 
previous studies.8–10 A previous validation study of spiro-
metry in CPRD GOLD found that of 96.5% of spirometry 
traces recorded at the general practice in COPD patients 
were of adequate quality where a respiratory clinician was 
able to make an interpretation.6 Of these, 27.9% were 
identified as post-bronchodilator FEV1, 7.2% were con-
firmed to be pre-bronchodilator FEV1, and for the remain-
ing measurements it was unclear if the measurements were 
pre- or post-bronchodilator.
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Patient Populations
In order to understand how the rate of FEV1 declines and 
its variation differs based on the criteria used to define 
longitudinal FEV1 decline, the following patient popula-
tions were created using specific criteria:
1. patients with at least two FEV1 measurements at least 
six months apart (base population). A minimum per-
iod of six months was chosen in order to estimate 
medium-term lung function decline;
2. patients in the base population excluding those who 
had an FEV1 greater than 10%, 20%, and 30% of 
their previous and subsequent FEV1 measurement. 
These measurements were regarded as potential 
measurement error, and patients were hence 
excluded;
3. patients in the base population excluding individual 
FEV1 measurements that were greater than 10%, 20%, 
and 30% of the previous and subsequent FEV1 mea-
surement. These measurements were regarded as 
potential measurement error and were hence excluded;
4. patients in the base population excluding measure-
ments that were within one week of an exacerbation 
of COPD (AECOPD) because AECOPD events are 
associated with decreased FEV1 both before and 
after an AECOPD;11
5. patients with at least three or four FEV1 measure-
ments, rather than two, of which at least two were at 
least six months apart (with no other time constraint on 
the other measurements). At least three and four mea-
surements were chosen following a common number 
of measurements used in RCT and cohort studies;
6. patients with at least two FEV1 measurements with 
at least six months or 1-year time intervals between 
all measurements. This was chosen following the 
nature of RCTs and cohort studies whereby spiro-
metry measurements are recorded at regular 
intervals;
7. patients in the base population with at least three 
years of follow-up following the maximum length of 
previous RCTs on lung function decline in COPD 
patients;12
8. patients in the base population and patients meeting 
inclusion criteria but who did require HES linkage 
eligibility. Approximately 60% of CPRD-GOLD 
patients are eligible for HES linkage, which can 
restrict populations.
Figure 2 illustrates how each patient population was iden-
tified using spirometry measurements.
Statistical Analysis
Baseline patient characteristics were described for all patient 
populations using means (standard deviation [SD]), medians 
(interquartile range [IQR]), and proportions (%). Baseline 
characteristics included age, gender, the closest recorded 
smoking status (smokers or ex-smokers) to index date, the 
closest BMI (underweight, normal, overweight, obese using 
standard categories) and modified MRC dyspnoea (0–4) 
recorded three years prior or two years after index date, 
severity of obstruction using FEV1% predicted (FEV1>80% 
predicted, FEV1 50–80% predicted, FEV1 30–50% predicted, 
and FEV1<30% predicted calculated using patient’s first FEV1 
measurement, height, and gender13), and AECOPD frequency 
1st January 2004 
1st COPD diagnosis, current registration 
date, up-to-standard date, date at age 35
+
Start of follow-up 
date: 1st FEV1










patients with linked HES data
Figure 1 Study design.
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and severity (none, 1 moderate and 0 severe, 2 moderate and 0 
severe, ≥3 moderate and 0 severe, 1 severe and any moderate, 
and ≥2 severe and any moderate) in the year prior to index 
date. Moderate AECOPD were defined as GP treated 
AECOPD and severe AECOPD were defined as hospitalised 
AECOPD. In addition, the median number of FEV1 measure-
ments (IQR and minimum/maximum number) and follow-up 
time were described for each population.
Mixed linear regression was used to estimate the rate 
of FEV1 decline in mL/year. Random effects included both 
random intercepts and random slopes allowing the inter-
cept and rate of decline to vary by patients. Models 
included a non-adjusted crude model, a minimally adjusted 
model adjusted for age and gender, a non-adjusted crude 
model for patients with complete baseline covariates, and 
a fully adjusted model adjusted for age, gender, smoking 
status, BMI, mMRC, FEV1% predicted, and AECOPD 
frequency. Within patient variation in FEV1 (mL) was 
estimated from mixed linear models.
In addition, a ninth analysis population was used to 
describe the rate of FEV1 decline using linear regression 
rather than mixed linear regression to understand how 
clustering at the patient level influences the rate of FEV1 
decline in the base population (population 1). Linear 
regression models included an unadjusted model, 
a minimally adjusted model, an unadjusted model for 
patients with complete baseline covariates, and a fully 
adjusted model adjusted for the same covariates as those 
used in the mixed linear regression model. Similarly, RCTs 
commonly use a baseline FEV1 measurement and 
a follow-up measurement to describe the change in FEV1 
over time. This method was used to compare the rates of 
decline against those estimated using linear regression and 
mixed linear regression methods. This was calculated 
using patient’s first and last FEV1 over follow-up divided 
by the time between these two measurements (in years) to 
estimate rate of FEV1 decline in mL/year.
Results
The numbers of patients included in each population var-
ied because of the different criteria for repeated FEV1 
measurements. Population eight included the greatest 
6 months











Figure 2 Patient populations. 
Notes: Patients with at least 2 FEV1 measurements at least 6 months apart with linked HES data; 2: Excluding patients with an FEV1 greater than 10%, 20%, or 30% of the 
previous FEV1; 3) Excluding measurements that are greater than 10, 20, 0r 30% of the previous FEV1 and subsequent FEV1; 4) Excluding measurements that are within 1 
week of an AECOPD; 5) At least 3 (or 4) FEV1 measurements with at least 2 at least 6 months apart; 6) FEV1 measurements that are all at least 6 months (*or 1 year) apart; 
7) At least 3 years of follow-up with at least 2 FEV1 measurements at least 6 months apart; 8) At least 2 FEV1 measurements at least 6 months apart (regardless of linked HES 
data).
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number of patients (N=125,682) as it did not require 
linked HES data and population two included the fewest 
number of patients because patients were excluded if they 
had an FEV1 that was greater than 10% of their previous 
and subsequent FEV1 (N=29,058). Table 1 summarises 
baseline characteristics for all populations. Populations 
were similar in terms of age, gender, smoking status, 
BMI, mMRC, and AECOPD frequency. However, popula-
tion two included fewer severely obstructed patients and 
more mild COPD patients (i.e., FEV1>80% predicted).
Most populations had a median of 4 FEV1 measure-
ments during follow-up; however, patients in population 
two (that excluded patients with an FEV1 greater than 10% 
or 20% of the previous and subsequent FEV1 measure-
ments) had fewer FEV1 measurements over follow-up with 
a median of 3. On the other hand, population five that 
included patients with at least 4 FEV1 measurements had 
a median of 6 measurements over follow-up. In addition, 
for population one, the median FEV1 measurement over 
follow-up was 1.5 L (IQR 1.08–2.03 (Supplementary 
Figure E1).
Rate of FEV1 Decline
Minimally adjusted and fully adjusted mean rates of FEV1 
decline in each population are shown in Figures 3 and 4. 
Estimates from crude analyses can be found in the supple-
mentary material (Tables E1–E9). Mean rates of FEV1 
decline were similar in all patient populations except for 
population two (i.e., exclusion of patients with FEV1 
greater than a) 10%, b) 20%, and c) 30% of the previous 
and subsequent FEV1 measurements. Minimally adjusted 
rates of FEV1 decline in population one and three-eight 
ranged from −18.7mL/year (95% CI −19.2 to −18.2) to 
−16.5mL/year (95% CI −17.3 to −15.7). The mean rates of 
FEV1 decline for population two was −79.4mL/year (95% 
CI −80.7 to −78.2) excluding those with an FEV1 greater 
than 10% of their previous FEV1, −57.1mL/year (95% CI 
−58.0 to −56.2) excluding patients with an FEV1 greater 
than 20% of their previous FEV1, and −46.8mL/year (95% 
CI −47.6 to −46.0) excluding patients with an FEV1 
greater than 30% of their previous FEV1.
Fully adjusted rates of FEV1 decline in population one 
and three-eight ranged from −14.6mL/year (95% CI −15.7 
to −13.6) to −9.8mL/year (95% CI −11.5 to −8.1). Fully 
adjusted mean rates of FEV1 decline for population two 
were −94.9mL/year (95% CI −97.5 to −92.3) excluding 
those with an FEV1 greater than 10% of their previous 
FEV1, −64.3mL/year (95% CI −66.1 to −62.5) excluding 
those with an FEV1 greater than 20% of their previous 
FEV1, and −51.4mL/year (95% CI −53.0 to −49.8) exclud-
ing those with an FEV1 greater than 30% of their previous 
FEV1.
It is important to note that minimally adjusted and fully 
adjusted models differed by patient numbers due to com-
plete case analysis. Tables E1–E8 provide further informa-
tion on unadjusted models, minimally adjusted models, 
unadjusted models in patients with complete data, and 
fully adjusted models. Unadjusted models in patients 
with complete baseline covariates were similar to fully 
adjusted models. Fully adjusted complete case analyses 
included fewer patients due to missing BMI, mMRC, and 
height (used to calculate FEV1% predicted).
Estimates using linear regression models were similar 
for unadjusted and minimally adjusted analyses; however, 
the rate of FEV1 decline was faster in fully adjusted 
analyses compared to rates estimated using mixed linear 
regression models (Table E9). The rate of FEV1 decline 
was also assessed in the base population (population 1) 
using patients first and last FEV1 measurements only. 
Overall, the mean unadjusted rate of FEV1 decline using 
this method was −16.4mL/year (SD 246.5).
Within patient variation of FEV1 in minimally adjusted 
mixed linear models ranged from 330.6 mL to 339.8 mL in 
populations one, four, five, seven, and eight. Within 
patient variation in FEV1 was slightly higher in population 
six at 350.7 mL. Population two had the lowest within 
patient variation in FEV1 at 195.5 mL, 191.2 mL, and 
202.5 mL after excluding patients with an FEV1 greater 
than 10%, 20%, and 30% of the previous FEV1 measure-
ments, respectively. See Supplementary Tables E1–E8 for 
further details on within patient variation in all models and 
populations.
Discussion
This piece of work set out to describe potential differences 
in patient characteristics, FEV1 variability and rates of 
FEV1 decline between COPD populations defined using 
different requirements around FEV1 measurements in rou-
tinely collected data using CPRD. Specifically, how dif-
ferent definitions around measurement error, number of 
measurements, time intervals between measurements, fol-
low-up time, and secondary care data linkage can lead to 
the selection of potentially different study populations. 
Overall, we found that regardless of the number of FEV1 
measurements, time intervals between measurements, fol-
low-up time, and secondary care data linkage, patient 
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demographics, within patient FEV1 variability, and rates of 
FEV1 decline remained consistent. Similarly, results were 
consistent in populations that excluded individual FEV1 
measurements that were likely due to measurement error. 
However, excluding patients (rather than individual mea-
surements) with likely measurement error led to the exclu-
sion of a specific group of COPD patients; severely 
obstructed patients (low FEV1% predicted). This could 
lead to selection bias in studies that aim to use 
a representative population of COPD patients. In addition, 
using mixed linear regression provided estimates that were 
different from those using linear regression, suggesting 
that clustering at the patient level is important when inves-
tigating the rate of FEV1 decline in routinely collected 
data.
The mean annual rates of FEV1 decline described in 
this study for populations one and three to eight were 
similar to those reported in previous studies of COPD 
patients.4,8,9 Interestingly, population two (those who 
were excluded due to potential measurement error) had 
faster rates of FEV1 decline. More patients with low FEV1 
% predicted were excluded in this population, which 
meant that there were more patients with milder COPD 
(higher FEV1% predicted) than all other populations. 
Previous studies have suggested that rates of FEV1 decline 
are faster in COPD patients with milder disease because 
they have more absolute lung function to lose at baseline 
than those with severe disease.14 This also suggests that 
patients with lower FEV1% predicted are more likely to 
have poorly recorded spirometry (potential measurement 
error). It is possible that patients with more severe disease, 
and lower FEV1% predicted, were more likely to perform 
poor spirometry, which might have contributed to the high 
variation seen in this group of patients. Whilst the best of 
three spirometry recordings should be recorded by health-
care practitioners, it is possible that only one spirometry is 
performed and recorded if patients are too severe to per-
form three in a row. It is also important to note that the 
increase in FEV1 by 10%, 20%, and 30% could be due to 
initiation of COPD medications, which can have an acute 
bronchodilation effect; however, studies have shown that 
this effect decreases over time in COPD patients on long- 
term treatment.15,16 Therefore, researchers should consider 
their research question prior to defining the rate of FEV1 
decline.
It is also important to note that fewer patients were 
included in models with patients who had complete base-
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of consistent recording of BMI and mMRC. Fully adjusted 
analyses produced slower mean rates of FEV1 decline 
compared to crude or minimally adjusted rates of decline. 
However, in the population that excluded patients due to 
potential measurement error (population two), fully 
adjusted mean rates of FEV1 decline were faster than 
crude and minimally adjusted models. Patient populations 
that excluded patients with potential measurement error 
and who had complete baseline data included slightly 
milder patients than the same population regardless of 
complete baseline data (data not shown). On the other 
hand, all other patient populations who had complete base-
line data had slightly more severe patients than the same 
populations regardless of complete baseline data. This is 
consistent with the theory that milder COPD patients 
might have faster rates of FEV1 decline due to initial 
lung function.14 Therefore, it is possible that missing base-
line variables could influence the type of patients included 
in a study, and the rate of FEV1 decline.
Lastly, simple linear regression provided estimates that 
were slightly faster than those using mixed linear regres-
sion. Previous studies have used linear regression to 
describe the rate of FEV1 decline.4,9,17 The limitation to 
this model is that within and between patient variations are 
not taken into consideration by the model. If similar types 
of patients are included and FEV1 is not highly variable 
within or between patients, then linear regression can be 
sufficient. However, due to the nature of CPRD, 
a routinely collected EHR, a wide variety of phenotypes 
can exist, and measurement error is possible therefore, 




Mean rate of FEV1 decline  
(age and sex adjusted)
(ml/year with 95% CI)
Main population 72,683 -18.0 (-18.7 to -17.2)






-79.4 (-80.7 to -78.2)
-57.1 (-58.0 to -56.2)
-46.8 (-47.6 to -46.0)
Excluding FEV1 measurements >X% of previous: >10%
>20%




-17.9 (-18.6 to -17.1)
-18.1 (-18.9 to -17.4)
-18.3 (-19.0 to -17.5)
Excluding measurements within one week of an AECOPD 70,887 -17.5 (-18.2 to -16.8)
Patients with ≥3 FEV1 measurements over follow-up
Patients with ≥4 FEV1 measurements over follow-up
58,121
44,673
-17.2 (-18.0 to -16.5)
-16.5 (-17.3 to -15.7)
Patients with measurements ≥6 months apart
Patients with measurements ≥1 year apart
72,683
65,875
-17.1 (-17.9 to -16.4)
-17.2 (-18.0 to -16.4)
Patients with ≥3 years of follow-up 59,185 17.7 (-18.4 to -16.9)
Patients without HES linkage 125,682 -18.7 (-19.3 to -18.2)
Main population using linear regression 72,683 -18.6 (-19.2 to -17.9)
-100 -80 -60 -40 -20 0 20
Figure 3 Minimally adjusted rates of FEV1 decline. 
Note: Adjusted for age and sex.
Populations Patient
N
Mean rate of FEV1 decline 
(fully adjusted)
(ml/year with 95% CI)
Main population 30,621 -11.6 (-13.1 to -10.1)
Excluding patients with FEV1 >X% of previous:   >10%
>20%




-94.9 (-97.5 to -92.3)
-64.3 (-66.1 to -62.5)
-51.4 (-53.0 to -49.8)
Excluding FEV1 measurements >X% of previous: >10%
>20%




-11.6 (-13.2 to -10.0)
-10.9 (-12.4 to -9.3)
-12.3 (-13.9 to -10.7)
Excluding measurements within one week of an AECOPD 29,924 -11.2 (-12.7 to -9.7)
Patients with ≥3 FEV1 measurements over follow-up
Patients with ≥4 FEV1 measurements over follow-up
23,696
17,350
-11.8 (-13.4 to -10.2)
-11.1 (-12.7 to -9.5)
Patients with measurements ≥6 months apart
Patients with measurements ≥1 year apart
30,621
26,556
-10.1 (-11.7 to -8.6)
-9.8 (-11.5 to -8.1)
Patients with ≥3 years of follow-up 22,627 -12.1 (-13.7 to -10.5)
Patients without HES linkage 67,391 -14.6 (-15.7 to -13.6)
Main population using linear regression 30,621 -21.6 (-22.6 to -20.5)
-100 -80 -60 -40 -20 0 20
Figure 4 Fully adjusted rates of FEV1 decline. 
Note: Adjusted for all baseline covariates.
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Previous studies (notably RCTs) have also estimated 
changes in FEV1 using two FEV1 measurements, one at 
baseline and one at follow-up.18,19 The nature of RCTs 
ensures that patients are similar in all arms of the trial and 
confounding is adjusted for by the study design. However, 
in CPRD, and other EHRs, this method could be easily 
biased by measurement errors, changes in maintenance 
therapies during follow-up, AECOPD events during fol-
low-up, and other everyday primary care factors. This 
method for estimating changes in FEV1 would require 
the two measurements to be accurate and not be recorded 
close to events that may influence FEV1 such as 
AECOPDs and changes in medication. Overall, in order 
to use as much data as possible over follow-up, and to 
consider varying changes in individual patient decline and 
initial lung function, mixed linear regression should be 
used when studying FEV1 using EHR.
One important limitation to acknowledge in this study 
is that whilst the majority (96.5%) of spirometry measure-
ments recorded in CPRD-GOLD are of adequate quality, 
pre, and post-FEV1 cannot always be distinguished. 
However, in a previous validation study of spirometry 
measurements in CRPD-GOLD, of those that could be 
distinguished, the majority of measurements were post- 
bronchodilator spirometry.6
Overall, this study aimed to explore different defini-
tions around longitudinal change in FEV1 in CPRD- 
GOLD and describe differences in populations created 
using these definitions. Previous studies have investigated 
how patient characteristics are associated with FEV1 
decline; however, the purpose of this study was to primar-
ily show how mean rates of FEV1 decline differed depend-
ing on the definition used.8–10,20,21 We found that in the 
cohorts that did not exclude measurements or individuals 
due to increases in FEV1, the mean rates of FEV1 and 
within patient variation remained similar. For this reason, 
the definition used to create population one (i.e., using all 
available FEV1 measurements over follow-up) could be 
used to describe the rate of FEV1 decline in a COPD 
population using CPRD data. However, researchers should 
consider their research question prior to the selection of 
the definition for rate of FEV1 decline.
Conclusion
Overall, the quality of FEV1 in CPRD is adequate for the 
purpose of studying FEV1 decline. We found that regard-
less of potential measurement error, number of FEV1 
measurements, time intervals between measurements, 
follow-up period, exclusion of specific FEV1 measure-
ments, and linkage to secondary care data, FEV1 variabil-
ity and rate of FEV1 decline remain similar in a COPD 
population. This suggests that CPRD is a good resource 
for investigating the rate of FEV1 decline in epidemiolo-
gical studies and pragmatic trials. However, researchers 
using EHR should be aware of the difference in rate of 
FEV1 decline and patient characteristics when excluding 
individuals with questionable data.
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